3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Ryan DuChanois of Solidec and Stephanie Campbell and Diana Murakhovskaya of The Artemis Fund. Photos courtesy

Editor's note: Welcome to another Monday edition of Innovators to Know. Today I'm introducing you to three Houstonians to read up about — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.

Ryan DuChanois, co-founder and CEO at Solidec

Ryan DuChanois pitched his company Solidec at CERAWeek, and took home a prize of $25,000. Photo via Solidec/LinkedIn

For the third year, the Greater Houston Partnership's Houston Energy Transition Institute hosted its startup pitch competition at CERAWeek by S&P Global. A dozen startups walked away with recognition — and three some with cash prizes.

Houston-based Solidec won the top prize for the TEX-E pitches. The company, which is working on a platform to produce chemicals from captured carbon, won first place and $25,000. Ryan DuChanois, co-founder and CEO, pitched at the event.

"This prize will help us scale up our technology from the lab at Rice University and ultimately fulfill our mission of capturing yesterday's emissions and generating tomorrow's fuels," the company writes in a post on LinkedIn. Read more.

Stephanie Campbell and Diana Murakhovskaya, co-founders and general partners of The Artemis Fund

Diana Murakhovskaya and Stephanie Campbell are co-founders of The Artemis Fund, a Houston-based, female founder-focused venture capital firm that just announced its $36 million fund II. Photo courtesy of Artemis

In 2019, Stephanie Campbell saw an opportunity in the market — investing in women-led startups, something that wasn't happening at the volume it should have been.

"When we looked around, we really wanted to solve the problem of why women only receive 2 percent of venture capital," Campbell says on the Houston Innovators Podcast.

As angel investors, Campbell and Diana Murakhovskaya, co-founders and general partners of The Artemis Fund, saw tons of promising women-led businesses. Read more.

Diana Murakhovskaya and Stephanie Campbell are co-founders of The Artemis Fund, a Houston-based, female founder-focused venture capital firm that just announced its $36 million fund II. Photo courtesy of Artemis

Houston VC leaders to empower female founders in fintech, commerce, and care with new $36M fund

HOUSTON INNOVATORS PODCAST EPISODE 228

In 2019, Stephanie Campbell saw an opportunity in the market — investing in women-led startups, something that wasn't happening at the volume it should have been.

"When we looked around, we really wanted to solve the problem of why women only receive 2 percent of venture capital," Campbell says on the Houston Innovators Podcast.

As angel investors, Campbell and Diana Murakhovskaya, co-founders and general partners of The Artemis Fund, saw tons of promising women-led businesses.

"We were finding these incredible female founders who we felt deserved capital to bring their innovations to the market because they're solving big markets and big problems But there was a disconnect in terms of their access and network," she continues.

The other issue, as Campbell explains, was that firms that did have a female-focused angle weren't leading these early-stage rounds. That's where Artemis comes in.

"Our goal was to be the leading firm for these overlooked, underserved markets that have the ability to deliver outsized returns," Campbell says.

Almost five years and around 20 investments later, The Artemis Fund has announced its second $36 million fund to continue to fund female-led upstarts with a tech solution within fintech, commerce, and care — the three pillars The Artemis Fund invests in.

"We really wanted to solve not just problems for women, which is a lot of what we do, but for families, small businesses, and immigrants, which is how we came around to these three verticals," Murakhovskaya says.

She goes on to explain that a significant percentage of adults are a part of the "sandwich generation" — caring not only for their own children, but for their aging parents. Innovations within caregiving can help this generation with their caregiving and maintain their role in the workforce. Additionally, over half the United States workforce is employed by small businesses, but these companies usually lack access to innovative technology.

"We're thinking about what founders are building in these industries to help these businesses thrive and leave these legacy assets to their children," Murakhovskaya says.

The Artemis Fund has announced that it's closed its second fund. Courtesy photos

Houston-based, female-focused VC closes $36M fund

fresh funding

A women-led venture capital group based in Houston has closed its second fund to continue its mission of supporting female-founded startups in fintech, commerce, and care.

The Artemis Fund announced its $36 million second fund this month. Co-founded in 2019 by General Partner Stephanie Campbell, General Partner Diana Murakhovskaya, and Venture Partner Leslie Goldman Tepper, the firm has invested in more than 20 female-led startups — with over 60 percent with Black, Latinx, or immigrant leadership.

"Many funds have come to market that focus on diverse founders. Few are also funding the technology to address key barriers faced by overlooked businesses, communities, and families in the U.S.," Artemis leadership writes in a news release.

"Artemis invests in the big personal, every day, economic problems that Silicon Valley doesn’t understand or know how to solve," the release continues. "We see massive opportunity in what many VCs will quickly write off as too small, too fragmented, and too hard to solve. If it keeps families and small business owners up at night, we are likely backing a company solving it."

Artemis Fund II includes support from limited partners Bank of America, Bank of Montreal, TIAA Nuveen’s Churchill Asset Management, Texas Capital Bank, Amazon, The Rockwell Fund, and Ballentine Partners.

“The Artemis Fund is not only breaking down barriers themselves, but they are also investing in companies looking to catalyze change," Hong Ogle, Houston president at Bank of America, says in the release. "Artemis keenly understands how to identify and support diverse entrepreneurs, which ultimately helps us toward achieving our goal to advance economic opportunity for all our communities."

The second fund has already made investments in five startups:

  • Alameda, California-based Hello Divorce, a tech-enabled guide to divorce with research, planning, therapy, and community support.
  • Gemist, based in Los Angeles, provides tech tools to jewelers.
  • West Palm Beach, Florida-based Max Retail, a platform to sell leftover inventory.
  • Payverse, headquartered in Sherman Oaks, California, is a cross border payment processor leveraging their modern processing platform.
  • New York-based Builder's Patch, a software platform that streamlines the process to finance the development and preservation of affordable multifamily housing for CRE lenders and developers.

If you feel like it's hard to find venture capitalists in Houston, you wouldn't be wrong, according to this Houston investor. Photo via Getty Images

Houston investor outlines how rare VCs are in Houston — and how to find them

guest column

As a venture capitalist and former startup founder living in Houston, I get asked a lot about the best way to find and connect with a venture capitalist in Houston. My usual advice is to start with a list, and reach out to everyone on that list. But no one has a comprehensive list. In fact, VCs are such a quiet bunch that I’ve yet to meet someone who personally knows everyone on this proverbial list.

So, I got together with a couple of VC friends of mine, and we put together our own Houston venture capitalist list.

There are, by our count, 11 active venture capital funds headquartered in Houston of any size and type, and outside of corporate venture capital and angel investors, there are 30 total venture capitalists running funds.

Houston has always been quite thin on the VC fund front. I’ve jokingly introduced myself for a while as “one of the 13 venture capitalists in Houston.”

Let’s put this scale in some brutal perspective. With 7.2 million people in the Greater Houston Metro Area, the odds of finding a partner level active venture capitalist in Houston is about 1 in 240,000, if you take a most expanded definition of venture capitalist that might come down to 1 in 100,000. We’re the fifth largest metropolitan area in the country with a tremendous economic engine; there is a ton of capital in Houston, but it’s residing in things like institutional fixed income and equities, real estate, wealth management, corporate, private equity, family office, energy and infrastructure Basically, mostly everywhere but in venture capital funds for tech startups.

By comparison, there are almost as many Fortune 500 CEOs in Houston — 24, by our count — as venture capitalists and fewer venture capitalists than Fortune 1000 CEOs, of which there are 43. That means running into a VC in the checkout line at HEB is about as rare as running into the CEO of CenterPoint, ConocoPhillips, or Academy. In fact, as there are 115 cities in the Greater Houston area, you are three times more likely to be a mayor in Greater Houston Area than a partner at an investor at a VC firm, and more likely to be a college or university president. While we’re at it, you’re 400 times more likely to be a lawyer, 250 times more likely to be a CPA, and over 650 times more likely to be a medical doctor.

Our 30 venture capitalists in the Greater Houston Area are spread across 20 firms and all major venture sectors and stages. Venture capitalist is defined for this list as a full time managing director or partner-level investment professional actively running a venture capital fund with limited partners, currently investing in new venture capital deals from their fund from seed to growth stage, and residing in the Greater Houston Metro area.

To get to 31 we added in a couple of people running venture set asides for PE funds, and a number who work from Houston for funds with no office here. We excluded CVCs, as the decision making is more corporate than individual and rarely includes the committed fund and carried interest structure that defines venture capital, and excluded professionals at angel networks, accelerators, and seed funds that provide investment, but don’t manage conventional venture capital funds, as well as PE funds that do the occasional venture deal. We might be able to triple the number if we include venture capitalists at any professional level, and add in those professionals at PE and angel and seed funds, and corporate venture capital teams who are actively investing. But we’ll get to those other sources of funding in the next list.

The 11 venture capital funds headquartered in Houston are: Mercury, Energy Transition Ventures (my fund), Montrose Lane (formerly called Cottonwood), Texas Medical Center Venture Fund, Artemis, New Climate Ventures, Fitz Gate Ventures, Curate Capital, Knightsgate Ventures, Amplo Ventures,and First Bight Ventures.

Another half a dozen firms have a partner level venture capital investor here, but are headquartered elsewhere: Energy Innovation Capital, Decarbonization Partners, 1984 Ventures, Altitude Ventures, Ascension Ventures, Moneta Ventures, and MKB & Co. Two others, CSL Ventures and SCF Partners, are local private equity funds with a venture capital partner in Houston and a dedicated allocation from a PE fund.

Culling these for partner or managing director level currently in Houston, in alphabetical order by first name, LinkedIn profile and all.

We may have missed a couple of VCs hiding in plain sight, as venture capital is a pretty dynamic business.

VCs are just rare. And yes, perhaps more rare in Houston than in California. Something less than 1 in 100 VCs in the country live in Houston. Across the US there are somewhere around 1,000 to 2,000 active venture capital firms, and maybe another 1,000 to 2,000 active US based CVCs — so, plus or minus maybe at most 4,000 to 5,000 currently active partner level venture capitalists in the country excluding CVC professionals (active VCs and VC funds are really hard to count).

Perhaps in the most stunning statistic, the 7,386 elected state legislators in the US today outnumber the total number of American venture capitalists. Luckily for startup founders, the venture capitalists are more likely to return your phone call.

------

Neal Dikeman is a venture capitalist and seven-time startup co-founder investing out of Energy Transition Ventures. He’s currently hosting the Venture Capital for First Time Founders Series at the Ion, where ETV is headquartered.

This week's roundup of Houston innovators includes Stephanie Campbell of HAN and The Artemis Fund, Larry Lawson of Proxima Clinical Research, and Vanessa Wyche of the Johnson Space Center. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from medical device development to fintech — recently making headlines in Houston innovation.

Stephanie Campbell, managing director of the Houston Angel Network and general partner at The Artemis Fund

Local investment leader talks trends in Houston venture capital activity

Stephanie Campbell joins the Houston Innovators Podcast last week to share some trends in early-stage investing. Photo courtesy of HAN

There were so many question marks at the beginning of the pandemic, especially for startup funding. Stephanie Campbell, who manages the most active angel network as well as a venture capital fund, says no one was sure how anything was going to pan out. Now, looking back on last year, VC did ok, she says on the Houston Innovators Podcast, and the Houston Angel Network saw membership growth.

"I think that given the markets with quite a bit of liquidity, people were looking for new and interesting ways to invest and make a return," Campbell says on the podcast. "In 2020, we actually grew by 30 percent and are up to 130 members of the Houston Angel Network and are continuing to grow through 2021."

Campbell shares more of her observations on the show and what she's focused on next. Click here to read more and stream the episode.

Larry Lawson, co-founder of Proxima Clinical Research

Larry Lawson joined InnovationMap for a Q&A about his startup's recent exit, his role on the boards of five med device companies, his investment activity, and more. Photo courtesy of Larry Lawson

When Larry Lawson started his career in the medical device industry, it was hard to get funding. The health tech founder and investor says if it wasn't oil or real estate, banks couldn't understand well enough to make a loan. So, he bootstrapped, raised from friends and family, and found venture capital support for his business endeavors over the years. Now, he's celebrating a $1.4 billion exit of his last business, Preventice Solutions, a deal that closed earlier this year.

The ecosystem in Houston has changed, he says, and he's seen it evolve as the Texas Medical Center grew and the Rice Business Plan Competition brought impressive student innovators from all around the globe.

"The health science community here in Houston is now known all over the world," he tells InnovationMap. "It's gonna just continue to grow and develop, and I hope to be a part of continue to be a part of it." Click here to read more.

Vanessa Wyche, director of Johnson Space Center

Vanessa Wyche is the first Black woman to lead a NASA center. Photo courtesy of NASA

For the first time, NASA has a Black woman at the helm of a space center. Vanessa Wyche has been named director of Johnson Space Center in Houston after serving as acting director since May 3.

"Vanessa is a tenacious leader who has broken down barriers throughout her career," Pam Melroy, deputy administrator of NASA, says in a news release. "Vanessa's more than three decades at NASA and program experience in almost all of the human spaceflight programs at Johnson is an incredible asset to the agency. In the years to come, I'm confident that Houston will continue to lead the way in human spaceflight."

As director of Johnson Space Center, Wyche now leads more than 10,000 NASA employees and contractors. Click here to read more.

Stephanie Campbell joins the Houston Innovators Podcast this week to share some trends in early-stage investing. Photo courtesy of HAN

Local investment leader talks trends in Houston venture capital activity

HOUSTON INNOVATORS PODCAST EPISODE 91

Backed by fresh funding from limited partners, The Artemis Fund is growing its portfolio at a time when funding female founders is more important than ever.

Stephanie Campbell — general partner and co-founder of The Artemis Fund, a Houston-based venture fund focused on supporting female founders — joined the Houston Innovators Podcast to discuss Artemis's first $15 million fund, which closed earlier this year.

"We raised more than half of the fund during the pandemic, so we know what it was like to be a founder raising funds in a pandemic," Campbell says on the episode. "Running a fund, I don't think a lot of people realize, is a lot like starting a startup, except we're raising money and backing startups at the same time."

The Artemis Fund invested in 10 startups — two in Houston — since its launch in 2019 and it was raising its fund I. Now, for 2021, Campbell and her partners — Leslie Goldman and Diana Murakhovskaya — are on the hunt for five more early-stage female-led companies to back.

"We're laser focused on finding the final five awesome women to add to our portfolio and then we'll start thinking seriously about launching fund II, probably at the end of the year," she explains.

Campbell says Artemis looks for seed-stage companies with a product already developed and ready to scale.

"We're really good at finding companies that have essentially bootstrapped, have a product in market with revenue, and we're usually that first institutional check," she says.

Within the companies that already make up the portfolio, a trend has emerged. Campbell says they are targeting fintech and e-commerce companies, as well as startups within caretech.

"These founders — all 10 of them — are in our mind creating a technology that helps people build wealth and care for their families and communities more sustainably," she says.

Speaking on VC trends, Campbell, who's also the managing director of the Houston Angel Network, says that despite the problems the pandemic provided the innovation ecosystem, HAN actually saw sizeable growth in membership and interest.

"I think that given the markets with quite a bit of liquidity, people were looking for new and interesting ways to invest and make a return," Campbell says on the podcast. "In 2020, we actually grew by 30 percent and are up to 130 members of the Houston Angel Network and are continuing to grow through 2021."

The organization pivoted to virtual pitches right off the bat and didn't slow down at all at the emergence of COVID-19. In fact, pitching at HAN has only gotten more competitive, Campbell says, and the membership is looking for early-stage companies that are out of just idea stage.

"It's getting harder and harder to get pre-seed funding in that first check for an idea stage," Campbell says on trends in the industry. "There are just so many deals that have done so much with so little to prove that they have product-market fit — and those tend to be the deals that pitch at our monthly meetings."

Campbell shares more about the trends in VC in Houston on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings